866-945-0263 | enquiries@arrowheadpublishers.com

Press Releases

December 1, 2010

Arrowhead’s New Report Assesses the State of Global Pain Therapeutics Market

Pain continues to present numerous challenges to the biopharmaceutical industry. According to the American Academy of Pain Medicine, over 76 million Americans suffer from pain. Indeed, pain affects more Americans than cancer, diabetes and cardiac disease combined. Current analgesics only provide modest relief, frequently carry black box safety warnings and are susceptible to abuse.

According to Arrowhead Publishers’ new report entitled The Global Pain Therapeutics Market: Market Trends and R&D Insights, the anticipated arrival of novel analgesics is set to transform this market. GW Pharmaceuticals’ Sativex (GW-1000), Allergan’s Botox (botulinium toxin), Merck’s Telecagepant (MK-0974), Novartis’ Canakinumab (ACZ885) and FoldRX Pharma’s Tafamidis (meglumine) will modernize pain management strategies. The market will enter a highly competitive, transitional era following the COX-2 saga. Investors must differentiate their products to gain blockbuster sales witnessed by Pfizer’s Lyrica (pregabalin) and Celebrex (celecoxib).

With numerous unmet needs, improved diagnosis of painful conditions, the advent of pharmacogenomics driving R&D and 10% of the global population regularly taking analgesia; the pain therapeutics market offers numerous lucrative commercial opportunities.  

The Global Pain Therapeutics Market: Market Trends and R&D Insights

  • Analyzes seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and pipeline analysis of each condition to maximize your product’s commercial success
  • Identifies the major challenges within pain R&D trends; exploring unmet needs, pain clinical trials, pharmacogenomics, animal pain models and functional imaging techniques
  • Analyzes both the clinical and commercial sides of the pain therapeutics market; including key late stage and Phase III/ II candidates and novel drug classes to watch

 

Report highlights


Although the analgesia market is highly competitive and heavily genericized, growth is expected. Improved diagnosis of fibromyalgia and neuropathic pain will be key driving factors. Sales of pain therapeutics could reach a massive $59 billion by 2015 in the seven major markets.  

Biomarkers will transform pain R&D away from the traditional linear, over-simplified model approach. Novel analgesia drug targets will be realized, streamlining clinical trials and optimizing candidate’s efficacy and safety profiles.  

Opioids will continue to form the backbone of pain relief due to improved physician prescribing confidence. By 2015, sales of opioids could reach $17 billion, with OxyContin (oxycodone; Purdue) remaining the top-selling branded analgesic until its patent expiration in 2013.

For more information about this report, CLICK HERE.

To order this report now, CLICK HERE.

Contact Us

PO Box 96
Chanhassen, MN 55317 USA
866-945-0263
www.arrowheadpublishers.com
enquiries@arrowheadpublishers.com

Speaker Opportunities

If you are interested in speaking at one of Arrowhead's conferences or would like to suggest a conference theme for which you have particular expertise, we'd like to hear from you.

Sponsor/Exhibitor Opportunities

Arrowhead sponsorship and exhibitor levels are designed to give your organization the highest level of exposure and opportunity to market products and branding in an environment that is targeted toward facilitating professional networking. We can also build tailor-made packages that will meet your organization's marketing budget and goals. Arrowhead sponsorships are proven to help grow businesses through direct and targeted exposure to industry leaders and decision makers. To gain critical industry exposure via our sponsorship and exhibiting opportunities, please contact us.